|Articles|June 15, 2004
Phakic IOL preserves endothelial cell count outcome measure
Study shows cell loss equal to natural aging, allowing IOL to be implanted in young patients
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
SpyGlass Pharma releases positive data from 2 trials of Bimatoprost Drug Pad-IOL System
2
Retina experts reflect on how OCT transformed patient care
3
AAO 2025: The ASPIRE phase 2B trial of UBX1325 head-to-head against aflibercept
4
Redefining glaucoma care: Where innovation meets clinical insight
5















































.png)


